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Abstract: 
Objective: Cancer cachexia is defined as: a ‘multifactorial syndrome’, and it has been suggested that a multitargeted 
approach is required in its management. High prevalence is seen within non-small cell lung cancer, and patients may 
continue to experience cachexia post end of anti-cancer treatment, and in the late/end stage. 
Material and Methods: Participants who had completed week 20/End of Trial visit in the main Auckland’s Cancer 
Cachexia evaluating Resistance Training (ACCeRT) study were invited to continue with treatment under compassionate 
use. Participants could continue with 2.09 g of eicosapentaenoic acid (EPA), 300 mg COX-2 inhibitor (celecoxib), once 
daily; plus two sessions per week of progressive resistance training (PRT), and 20 g oral essential amino acids (EAA); 
high in leucine, in a split dose over three days post each session. Data was collected on the acceptability, compliance 
and adherence to medication/PRT sessions. Secondary endpoints included: change in body weight and fat free mass, 
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handgrip and leg strength, the Functional Assessment of Anorexia/Cachexia Therapy, Multidimensional Fatigue Symptom 
Inventory-Short Form, World Health Organization Quality of Life — BREF, Glasgow prognostic score, and pro-inflammatory 
cytokines.
Results: All six participants, who completed the main ACCeRT study, opted to continue with compassionate use. 
Acceptability remained high, with overall compliance to last study/PRT visit of 81.0% for EPA, 98.8% for celecoxib, 78.9% 
for PRT and 77.2% for EAA. Participants continued to lose body weight and Fat-Free Mass, along with reduced albumin 
and increased C-Reactive protein levels. Mean time on compassionate study treatment was 78 days, and with a mean 
overall survival of 257 days (140 + 117).
Conclusion: Non-small cell lung cancer (NSCLC) cachectic patients are willing to be enrolled onto a multi-targeted 
treatment regimen, and may benefit from cachexia symptom management even during their late/refractory stage. 
Keywords: Refractory cancer cachexia, Resistance Training, NSCLC cachectic patients, multi-targeted treatment 
Introduction
 Cachexia still remains a challenge within the oncology 
population. A recent, cross-sectional study investigated 
the prevalence of cancer cachexia in 386, of 426 eligible 
patients attending selected hospitals within Norway.1 
Prevalence of 21.0% was seen amongst outpatients; 
increasing to 51.0% within the inpatient population. High 
levels were again reported within the lung cancer population, 
with 36.0% amongst outpatients and increasing to 83.0% 
of inpatients. Patients were asked if they required either 
decreased or increased attention to their weight. Fifteen 
percent of outpatients and 20.0% of inpatients requested: 
“more or a lot more focus”, on this condition.1
 It has long been established that cachectic cancer 
patients have been associated and/or documented to have 
lower response rates to traditional chemotherapy as well 
as shorter median survival,2 which has been attributed to a 
number of factors. Firstly, because chemotherapy dosage 
is based on body surface area, thinner patients receive a 
lower dose of chemotherapy. Secondly, treatment breaks, 
due to chemotherapy toxicities, are higher in this population 
of patients.3 Thirdly, previous chemotherapy treatments 
and concurrent multi-modality treatments e.g., surgery 
and radiotherapy will also affect nutritional status, which 
further confound the condition. A retrospective review 
suggested that metastatic melanoma patients treated with 
chemotherapy, immunotherapy and targeted therapy with 
a body mass index (BMI) of either overweight or obese, 
as classified by the World Health Organisation (WHO), had 
improved progression-free survival and overall survival 
when compared with patients of normal weight.4 Improved 
survival within early obese cancer patients has been 
termed as the: ‘obesity paradox’5, and has been shown 
in a number of different cancers.6 Failure to respond 
to pembrolizumab has been recently identified, due to 
elevated protein catabolism and clearance seen within 
cancer cachectic patients.7,8 With the increase in the use of 
immune checkpoint inhibitors that have revolutionized the 
current treatments in oncology, this highlights the need to 
diagnose and support cachectic patients throughout their 
anti-cancer treatments and beyond.
 Cancer cachexia has recently been defined as 
multifactorial; including, elements of decreased total body 
weight, adjoined with skeletal muscle loss contributing to 
impaired function, respiratory complications and fatigue, 
decreased food intake, metabolic changes, increased 
inflammation and catabolism; affecting the patients’ overall 
quality of life.9,10
Journal of Health Science and Medical Research                            J Health Sci Med Res..................3
Rogers ES, et al. Acceptability, Compliance, and Safety of NSCLC 
 Multi-targeted/multi-modal studies have been 
designed to address these factors, and recently the results 
of the Pre-Multimodal Exercise/Nutrition/Anti-inflammatory 
Treatment for Cachexia (Pre-MENAC) study have been 
published. This study investigated the use of standard 
cancer care versus a multi-modal regimen, comprising 
of a single baseline session of nutritional counselling 
(approximately 30 minutes), eicosapentaenoic acid (EPA) 
via two 220 mL cartons of oral nutritional supplement 
(Prosure © Abbott) equaling a net intake of 2 g/day, 300 mg 
celecoxib OD, twice weekly home-based aerobic sessions 
(approximately 30 minutes) and thrice weekly resistance 
training of six individualized exercises (approximately 20 
minutes). The study period of six weeks ran concurrently, 
with cycles I and II of chemotherapy in non-small cell lung 
cancer (NSCLC), and pancreatic cancer patients with less 
than 20.0% weight loss over the preceding six months.11 
This study recruited pre-cachexia/cachexia patients, with 
the results demonstrating  no significant difference between 
groups on muscle mass, as assessed by computerized 
tomography (CT) derived measures, or physical activity 
assessed by 6MWT and ActivPAL. Compliance rates of 
60.0% for exercise, 48.0% for nutritional supplement and 
76.0% for celecoxib were observed.11
 Anamorelin is the only registered drug for the 
treatment of cancer cachexia recently approved by Japan 
in December 2020.12 The intervention(s) being tested within 
the ACCeRT study are an alternative treatment regimen.
 The study was designed to address cachectic 
factors within a multi-targeted regimen, within end-
stage/refractory cachectic NSCLC patients.13 The study 
combination was chosen to increase muscle anabolism, 
using progressive resistance training (PRT) and essential 
amino acids (EAA) high in leucine, post exercise as well 
as to target and decrease the proinflammatory cytokines by 
using a cyclooxygenase-2 inhibitor (celecoxib) and EPA. 
Results from the main study showed high acceptability, and 
compliance rates of 86.8% for EPA, 100.0% for celecoxib, 
94.4% for PRT/exercise, and 76.5% for EAA within the 
treatment group at week 20. Trends in efficacy, in terms 
of improvement and/or stability in cachexia markers, were 
seen within magnetic resonance imaging (MRI) muscle 
volume, albumin, and C-reactive protein (CRP) levels within 
both arms.14 Participants who had completed the ACCeRT 
main study could continue with medication and/or exercise 
sessions post end of the main study under compassionate 
use (CU). Data on the ongoing acceptability, compliance and 
safety of this multi-targeted regimen in refractory cachectic 
NSCLC patients will be used to calculate the power and 
number of participants required for a future phase II study.
Material and Methods
 Northern Y Ethics Committee, Hamilton, New 
Zealand (NTY/11/06/064) approved the published study 
protocol.13 The study was registered with the Australian and 
New Zealand Clinical Trials Registry, and complied with the 
International Ethical Guidelines for Biomedical Research 
Involving Human Subjects, Good Clinical Practice Guidelines, 
and the Declaration of Helsinki. Participants consisted of 
those whom had completed week 20/End of Trial (EOT) 
visit in the main ACCeRT study, had maintained an Eastern 
Cooperative Oncology Group Performance Status (ECOG-
PS) ≤2, and for which the investigator considered suitable 
to continue to receive additional treatments and exercise 
sessions. Participants were permitted to withdraw at any 
time, or at the discretion of the investigator; due to further 
progression of their disease.
 Procedures
 All participants could choose to continue to orally 
receive 2.09 g of EPA, plus 300 mg of celecoxib once 
daily. Arm A participants could choose to commence with 
the addition of two PRT sessions per week (Tuesdays 
and Fridays), followed by 20 g EAA high in leucine in split 
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doses over the following three days. Arm B participants 
could choose to continue with PRT/EAA. Dose reductions 
or interruptions of all study medications, and exercise 
sessions were permitted. The intention of compassionate 
PRT differed depending on study randomisation to either 
Arm A or Arm B within the main study. Those participants 
that had completed the 20-week PRT programme (Arm 
B) had the option to continue with resistance training. The 
intention for this group of participants was to maintain the 
same training intensity and volume achieved at week 20/
EOT of the PRT programme. Those participants that were 
not allocated to the PRT exercise group (Arm A) had the 
option of starting the PRT programme, using the same 
exercise programme designed from the main study. All 
participants were medically assessed every four weeks.
 
 Outcomes
 Data was collected on the acceptability of a multi-
targeted regimen of supportive care in cachectic NSCLC 
participants continuing with compassionate use. Acceptability 
was assessed by the analysis of a patient rated Likert scored 
questionnaire, asking 10 questions on the acceptability of 
the above multi-targeted approach. Likert scores had a 
range of five, five being: ‘strongly agree’, and one being: 
‘strongly disagree’, with higher scores representing higher 
acceptability of the study medication and/or exercise 
programme. Secondary endpoints were continued over 
from the main study, and included the change from 
baseline in body composition (fat-free mass (FFM), total 
body weight, and fat mass), as measured by Bioelectrical 
Impedance Analysis (BIA) (Tanita), muscle strength (hand 
grip dynamometry and isometric knee extension, measured 
by the use of a customised rig attached to a load cell). 
Symptom burden was measured with the anorexia-cachexia 
scale and physical well-being scale from the Functional 
Assessment of Anorexia/Cancer Therapy (version 4). 
Fatigue was measured by The Multidimensional Fatigue 
Symptom Inventory-Short Form, and overall quality of life 
by WHOQOL-BREF. Proinflammatory cytokine analysis 
(IL-1β, IL-6, and TNF-α) was measured by Luminex 
MAGPIX®. Albumin and CRP levels were incorporated into 
the Glasgow Prognostic Score. Compliance results were 
analysed as percentage of the total study medication, and 
percentage of attendance of the total study PRT sessions. 
All the above data were collected every four weeks, and 
study participants were followed up for overall survival 
Results
 Sixty-nine patients were screened, resulting in 20 
patients being enrolled onto the main study (Figure 1 – 
Consolidated Standards of Reporting Trials profile). All six 
participants, completing week 20/EOT visit from the main 
study continued with study medication, and either continued/
began PRT sessions and EAA under CU (two allocated to 
Arm A, and four allocated to Arm B). Baseline characteristic 
data is shown in Table 1.
 The acceptability questionnaire was completed 
at each monthly CU visit, as shown in Table 2. Results 
showed high mean acceptability scores of 4 to 5 for EPA, 
celecoxib, PRT and EAA, and commitment to continue with 
the regimen from CU 1 through to CU 5 visit. 
 Compliance data is shown in Table 3 (deemed as 
>50.0% for each participant) and was 80.0% (n=4/5) for 
EPA, 100.0% (n=5/5) for celecoxib, 83.3% (n=5/6) for the 
PRT component, and 75.0% (n=3/4) for EAA. 
 Overall compliance was 81.0% for EPA, 98.8% for 
celecoxib, 78.9% for PRT, and 77.2% for EAA; as shown 
in Table 4. These results conclude that on average, the 
administration of EPA, celecoxib, PRT and EAA at this dose 
and frequency was acceptable within this population; with 
three of the six participants continuing with all four elements 
of the multi-targeted regimen.
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PRT=progressive resistance training, CU=compassionate use, EOT=end of trial
Figure 1 Consolidated Standards of Reporting Trials




At ACCeRT entry At ACCeRT CU entry
Age (years) 63.7 (42 to 71)
Race
   European 4
   Māori 2
Gender
   Male 4
   Female 2
Weight loss (%)
   All -7.9 (-5.0 to -9.8)a -3.7 (-10.2 to +4.4)b
   0.0 to 5.0% 0 2
   5.0 to 10.0% 5 3
   +0.0 to +5.0%     0 1
   Low BMI 1a 0
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At ACCeRT entry At ACCeRT CU entry
Body weight (kg)
   All 72.8 (45.1 to 89.1)c 69.7 (47.1 to 87.7)d
   Male 78.3 (70.7 to 89.1)c 74.1 (66.7 to 87.7)d
   Female 61.9 (45.1, 78.6)c 60.9 (47.1, 74.6)d
Time since diagnosis (days) 429 (125 to 920)e
Diagnosis NSCLC
   Adenocarcinoma 4
   Squamous 2
Albumin (g/L) 37.5 (25 to 44)c 34.8 (27 to 40)d
CRP (mg/L) 37.8 (5 to 62)c 86.3 (2 to 211)d
GPS 0.8 (0 to 2)c 1.2 (0 to 2)d
aWeight loss defined as percentage weight loss at main ACCeRT study entry. *one participant study entry with low BMI.
bWeight loss/gain defined as weight change from Random visit to week 20/EOT visit of main ACCeRT study.
cData at study Random visit.
dData at week 20/EOT visit/start of CU.
eTime since diagnosis defined as histology date to date of main ACCeRT study entry.
CU=compassionate use, BMI=body mass index, NSCLC=non-small cell lung cancer, CRP=C-reactive protein, GPS=glasgow prognostic 
score, EOT=end of trial, ACCeRT=Auckland’s Cancer Cachexia evaluating Resistance Training 
Table 2 Acceptability questionnaire results
CU 1 CU 2 CU 3 CU 4 CU 5
EPA acceptable (5) 5a 5a
Celebrex acceptable (5) 5b 5b 4.5a 5c 5c
PRT acceptable (5) 5b 5b 4.5a 5c 5c
EAA acceptable (5) 5a 5a 4c
Continue with exercise and medication (5) 5b 5b 4.5a 5c 5c
Total number of participants in the study 5 5 2 1 1
Total number of participants in the study with data 4 3 2 1 1
an=2 participants taking either the medication/exercise. 
bn=3 participants taking either the medication/exercise. 
cn=1 participant taking either the medication/exercise.
Highest score available for each question within parenthesis. 
EPA=eicosapentaenoic acid, PRT=progressive resistance training, EAA=essential amino acids, CU=compassionate use 
One Arm A and one Arm B particpant did not complete the acceptability questionaire during compassionate use (CU).
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Table 3 Compliance table for individual participants completing compassionate use
                   Percentage taken of the total study dose/attendance at sessions
EPA Celecoxib PRT/Days PRT EAA
Arm A 100 0 5 sessions 100 21
25/25 days 0 25 days 5/5 21/100 g
Arm A 4.8 93.9 48 sessions 79.2 0
8 days* 155 days* 165 days 38/48 0
Arm B 100 100 16 sessions 81.3 93
53/53 days 53/53 days 53 days 13/16 186/200 g*
Arm B 100 100 21 sessions 85.7 100
71/71 days 71/71 days 71 days 18/21 420/420 g
Arm B 0 100 25 sessions 32 0
0 87/87 days 87 days 8/25 0
Arm B 100 100 20 sessions 95 94.7
67/67 days 67/67 days 67 days 19/20 360/380 g
*participant decision to stop
CU 1 equals 28 doses of EPA and celecoxib, 8 PRT sessions, and 160 g of EAA.
CU 2 equals 56 doses of EPA and celecoxib, 16 PRT sessions, and 320 g of EAA.
CU 3 equals 84 doses of EPA and celecoxib, 24 PRT sessions, and 480 g of EAA.
CU 4 equals 112 doses of EPA and celecoxib, 32 PRT sessions, and 640 g of EAA.
CU 5 equals 140 doses of EPA and celecoxib, 40 PRT sessions, and 800 g of EAA.
EPA=eicosapentaenoic acid, PRT=progressive resistance training, EAA=essential amino acids, CU=compassionate use
Table 4 Percentage compliance table for participants 
 completing compassionate use
EPA Celecoxib PRT EAA 
Arm A 100   100 21
Arm A 4.8 93.9 79.2  
Arm B 100 100 81.3 93
Arm B 100 100 85.7 100
Arm B   100 32  
Arm B 100 100 95 94.7
Mean 81.0a 98.8b 78.9 77.2c
an=5 participants taking EPA. One previous Arm B participant 
declined EPA. 
bn=5 participants taking celecoxib. One previous Arm A participant 
did not take celecoxib, due to remaining on diclofenac 100 mg 
sustained release.
cn=4 participants taking EAA. One previous Arm A and one previous 
Arm B declined EAA.
EPA=eicosapentaenoic acid, PRT=progressive resistance training, 
EAA=essential amino acids, CU=compassionate use
 Secondary endpoints
 Individual participant mean weight, FFM, albumin and 
CRP level, per each study visit, is shown in Table 5. Three 
participants continued to lose total body weight, and all four 
participants continued to lose FFM throughout CU visits. At 
CU 1 (main study week 20 + week 4 CU=24 weeks) there 
was a mean percentage weight change of -5.6% (range 
-11.5 to +5.1%, n=3), with a mean FFM change of -3.2% 
(range -7.0 to +1.8%, n=3). At CU 2 (28 weeks) there was 
a mean percentage weight change of -6.5% (range -11.0 
to +2.2%, n=3), with a mean FFM change of -3.4% (range 
-4.6 to -1.5%, n=3). At CU 3 (32 weeks) there was a mean 
percentage weight change of -6.7% (-12.0%, -1.3%, n=2), 
with a mean FFM change of -4.7% (-8.1%, -1.3%, n=2). 
For the remaining participant results at CU 4 (36 weeks) 
there was a percentage weight change of -13.0%, and a 
FFM change of -7.7%. At CU 5 (40 weeks) there was a 
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percentage weight change of -12.9%, and a FFM change 
of -4.6%. This indicates relatively low FFM loss of -3.2% 
to -4.6% over the 20-week main study, plus a further 4 to 
20 weeks during compassionate use.
Table 5 Individual participants secondary outcome results
Arm A Randomisation Week 20 CU 1 CU 2 CU 3 CU 4 CU 5
Weight (kg) 70.7 68.2 62.6 62.9 62.2 61.5 61.6
Difference -2.5 -8.1 -7.8 -8.5 -9.2 -9.1
% difference -3.5% -11.5% -11.0% -12.0% -13.0% -12.9%
FFM (kg) 54.6 53.0 50.8 52.3 50.2 50.4 52.1
Difference -1.6 -3.8 -2.3 -4.4 -4.2 -2.5
% difference -3.0% -7.0% -4.2% -8.1% -7.7% -4.6%
Albumin (g/L) 35 35 28 30 34 35 33
Difference 0 -7 -5 -1 0 -2
% difference 0.0% -20.0% -14.3% -2.9% 0.0% -5.7%
CRP (mg/L) 9 12 32 30 13 32 27
Difference +3 +23 +21 +4 +23 +18
% difference +33.3% +255.6% +233.3% +44.4% +255.6% +200.0%
Arm B Randomisation Week 20 CU 1 CU 2 CU 3 CU 4 CU 5
Weight (kg) 78.9 73.9 70.7 70.4
Difference -5.0 -8.2 -8.5
% difference -6.3% -10.4% -10.8%
FFM (kg) 60.4 58.9 57.7 59.5
Difference -1.5 -2.7 -0.9
% difference -2.5% -4.5% -1.5%
Albumin (g/L) 44 38 41 43
Difference -6 -3 -1
% difference -13.6% -6.8% -2.3%
CRP (mg/L) 37 211 42 62
Difference +174 +5 +25
% difference +470.3% +13.5% +67.6%
Arm B Randomisation Week 20 CU 1 CU 2 CU 3 CU 4 CU 5
Weight (kg) 78.6 74.6 77.6
Difference -4 -1
% difference -5.1% -1.3%
FFM (kg) 47.2 46.1 46.6
Difference -1.1 -0.6
% difference -2.3% -1.3%
Albumin (g/L) 40 35 39
Difference -5 -1
% difference -12.5% -2.5%
CRP (mg/L) 5 2 4
Difference -3 -1
% difference -60.0% -20.0%
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 At CU 1 there was a mean percentage albumin 
change of -12.9% (range -20.0 to -6.8%, n=3), with a mean 
CRP change of +78.8% (range -32.7 to +255.6%, n=3). 
At CU 2 there was a mean percentage albumin change 
of -8.2% (range -14.3 to -2.3%, n=3), with a mean CRP 
change of +103.9% (range +10.9 to +233.3%, n=3). At CU 
3 there was a mean percentage albumin change of -2.7% 
(-2.9%, -2.5%, n=2), with a mean CRP change of +12.2% 
(-20.0%, +44.0%, n=2). For the remaining participant results 
at CU 4 there was an albumin change of 0% and a CRP 
change of +255.6%. At CU 5 there was an albumin change 
of -5.7% and a CRP change of +200.0%. Percentage 
change was high for one participant, who had a 20.0% 
reduction in their albumin level during the first cycle of 
second-line chemotherapy. It is difficult to discuss trends 
in CRP levels during compassionate use, due to some 
participants receiving corticosteroids during chemotherapy 
and radiotherapy; therefore, this not further discussed here.
 High scores on the primary endpoint acceptable 
questionnaire showed that the participants found engaging 
in the PRT sessions acceptable. At each session, 
participants were assessed, and the exercise programme 
was adapted. Results show that both Arm A participants 
that transferred onto PRT sessions achieved the planned 
programme and BORG-Rating of perceived exertion (BORG 
RPE) 11: ‘light’ at the end of phase I/week 4 (CU 1=total 
24 weeks). The designed low volume, low intensity to a 
moderate volume, and moderate-high intensity training 
programmes were both safe and acceptable within a NSCLC 
end-stage cachectic population. Additionally, it was possible 
to modify the exercise prescription at different time points 
for each participant, in an individual adaptive manner, due 
to ongoing chemotherapy, radiotherapy or further disease 
progression.
 As per Figure 2, there was an overall mean time 
on the main ACCeRT study + CU of 218 days (range 165 
to 305) and mean overall survival of 257 days (range 196 
to still alive). Interestingly, one participant had relevant 
stable body weight as well as ECOG-PS and was offered 
a second line of chemotherapy during CU.
 There were no treatment-related deaths, nor 
exercise-related events, seen within both the main study 
and during compassionate use. As per the published 
main study results, there was one possible case of study 
medication induced atrial fibrillation within one Arm A 
participant.14 
Table 5 (Continued)
Arm B Randomisation Week 20 CU 1 CU 2 CU 3 CU 4 CU 5 
Weight (kg) 45.1 47.1 47.4 46.1
Difference +2 +2.3 +1
% difference +4.4% +5.1% +2.2%
FFM (kg) 39.2 39.8 39.9 37.4
Difference +0.6 +0.7 -1.8
% difference +1.5% +1.8% -4.6%
Albumin (g/L) 25 27 22 23
Difference +2 -3 -2
% difference +8.0% -12.0% -8.0%
CRP (mg/L) 55 46 37 61
Difference -9 -18 +6
% difference -1.4% -32.7% +10.9%
FFM=fat free mass, CRP=C-reactive protein, CU=compassionate use
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 In summary, the first Arm A participant chose to 
continue with the daily dose of EPA and to begin PRT and 
EAA only. This participant was continuing on daily diclofenac 
100 mg sustained-release for bilateral hip osteoarthritis 
pre-study entry and completed compassionate use for 25 
days and five PRT sessions. Compassionate treatment 
and PRT was discontinued by the study team at week 23 
(week 20 main study + week 3 CU), due to dislocation 
of the hip and pelvic pain, and was required to remain in 
hospital for an extended time. Last recorded ECOG PS=1: 
there were no other data collected for this participant. The 
second Arm A participant chose to continue with the daily 
dose of EPA, celecoxib and to begin PRT only. EAA was 
declined, due to all the other medications this participant 
was taking. This participant decided to stop EPA after 8 
days of compassionate use, with a compliance of 4.8%. 
They had completed compassionate use for 165 days and 
48 PRT sessions. Compassionate treatment and PRT 
was discontinued at this participants request at week 44 
(week 20 main study + week 24 CU), due to moving to a 
property outside of the city. Last recorded ECOG PS=2. 
The first Arm B participant chose to continue with the daily 
dose of EPA, celecoxib, PRT and EAA, and completed 
compassionate use for 53 days and 16 PRT sessions: 
compassionate treatment and PRT was discontinued at 
week 28 (20 main study + week 8 CU) due to death. Last 
recorded ECOG PS=2:  there were no other data collected 
for this participant. The second Arm B participant chose to 
continue with the daily dose of EPA, celecoxib, PRT and 
EAA, and completed compassionate use for 71 days and 
21 PRT sessions. Compassionate treatment and PRT was 
discontinued at week 31 (week 20 main study + week 11 
CU) due to death. Last recorded ECOG PS=2. The third 
Arm B participant stopped EPA at week 11, and received 
a reduced dose of EAA from week 3 in the main study, 
and completed compassionate use for 87 days and 25 
PRT (32.0%) sessions. This was due to the logistics of 
caring for a young family, and attending exercise sessions. 
Compassionate treatment and PRT was discontinued at 
the participants request at week 33 (week 20 main study 
*One participant (participant 5) still alive at time of submission.
ACCeRT=Auckland's Cancer Cachexia evaluating Resistance Training, CU=compassionate use
Figure 2 Individual participants days on Auckland’s Cancer Cachexia evaluating Resistance Training main study plus 
 compassionate use, and overall survival from main study entry
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+ week 13 CU) due to moving to another island. Last 
recorded ECOG PS=2. The fourth Arm B participant chose 
to continue with the daily dose of EPA, celecoxib, PRT and 
EAA, and completed compassionate use for 67 days and 
20 PRT sessions. Compassionate treatment and PRT was 
discontinued by the study team at week 10 (week 20 main 
study + week 10 CU), due to progression of disease and 
the requirement for hospice respite care. Last recorded 
ECOG PS=2.
Discussion
 The continuation of the ACCeRT study regimen 
under compassionate use further demonstrates the 
feasibility and acceptability in patients with refractory cancer 
cachexia and NSCLC. The multi-targeted regimen has 
shown further safety without any exercise-induced adverse 
events.
 It was observed that three of the four participants 
in the 24th week of the intervention still experienced an 
overall loss of total body weight and FFM. The additional 
data gained post week 20/EOT visit helps support the 
longer study time period utilised within the main ACCeRT 
study, along with gaining new data in this population over 
an extended time period.
 Median survival within the ACCeRT main study of 
96 days within Arm A (EPA + celecoxib), versus 136 days 
within Arm B (EPA, celecoxib, PRT + EAA), versus 257 
days in the main ACCeRT study + CU (one participant 
still alive at submission), is comparable to the followings 
of two randomized controlled trials (RCT) in late cachexia/
refractory cachexia; wherein anti-cancer treatment was not 
permitted. Gordon et al., investigated the use of 200 mg 
thalidomide OD verses a placebo in advanced pancreatic 
cancer patients, with at least a 10.0% weight loss over 
the previous six months; with a planned study period of 
24 weeks. Fifty patients were randomised (1:1), with 20 
participants achieving eight weeks of treatment. There was 
a median survival of 148 days within the thalidomide group 
versus 110 days within the placebo group (p-value=0.450).15
 This was followed by the RCT of EPA versus 
placebo within lung and gastrointestinal cancer patients, 
with ≥5.0% of weight loss of pre-illness stable weight. 
Participants were randomised to either 4 g EPA, 2 g EPA, 
or a placebo OD. There was a study period of eight weeks, 
with participants permitted to continue with EPA post EOT 
under compassionate use.16 Five hundred and eighteen 
patients were randomised (1:1:1), with 50.0% achieving eight 
weeks of treatment. There was a median overall survival of 
142 days within 4 g EPA, versus 155 days within 2 g EPA, 
versus 140 days within the placebo group (p-value=0.750).
This is in contrast to the survival data within the ROMANA 
1 and 2 studies.17,18 Whereas, these results showed no 
difference between groups with median survival over one 
year of 8.9 months (~270 days) within the anamorelin 
group versus 9.2 months (~280 days) within the placebo 
group (p-value=0.470). Additionally, similar survival rates 
were seen between groups, with deaths of 10.5% in the 
anamorelin group versus 13.8% within the placebo group 
in the ROMANA 3 extension study.18 
 Other studies, within the pre-cachexia/cachexia 
phase, have included the Espindolol study, which again 
showed no significant difference in survival between the 
high-dose group (61 weeks, ~427 days), low-dose group 
(50.9 weeks, ~356 days) and placebo group (42.3 weeks, 
~296 days).19 The only other multi-targeted study (Pre-
MENAC) showed a median survival of 10 months (~304 
days) within the treatment group versus 8 months (~243 
days) within the control group (p-value=0.570).11 A non-
significant difference in overall survival was seen between 
groups in the phase II Enobosarm study, again in patients 
with pre-cachexia/cachexia.20 Interestingly, none of the 
above studies have shown an overall survival benefit by 
addressing pre-cachexia/cachexia in patients undergoing 
anti-cancer treatment.
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 ACCeRT is the first study to investigate a multi-
targeted regimen; including the use of exercise, in a 
refractory cachexia population. High mean acceptability 
scores of 4 and 5 were maintained throughout CU.
 The ACCeRT study was appropriately designed 
to evaluate the feasibility of a conservative PRT protocol 
(given cachexia patient considerations). As PRT was well 
tolerated during the CU phase, future studies should look to 
optimise the PRT to minimise muscle wasting, and maintain 
patient functional outcomes e.g., activities of daily living, 
and fatigue. 
 The ACCeRT CU data has a number of limitations. 
Firstly, the attrition rate within both Arms within the main 
study, with two allocated to Arm A and four allocated to 
Arm B proceeding onto this compassionate use study. 
Interestingly, participants who continued post week 12 
study visit, then went on and completed the week 20/EOT 
study visit and then further continued with post study CU. 
Secondly, it must be acknowledged that the open-label 
design, and that participants could decide on which elements 
of the regimen to continue with increases the risk of bias 
of these results. Thirdly, CU body composition was limited 
to BIA data only, additional CU MRI analysis would have 
strengthened the skeletal muscle changes. 
Conclusion
 In conclusion ACCeRT is the first study to utilise a 
multi-targeted regimen in the refractory cancer population; 
therefore, a comparison with other research studies cannot 
be made at this point. The post main ACCeRT study CU 
results indicate that patients may benefit from being enrolled 
onto a multi-targeted cachexia symptom management 
treatment regimen, even during the late/refractory stage. 
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